Public-record receiptI-MEOfficial filing linked

Angus King disclosed SELL $LLY

Here’s the public record: who traded, what they disclosed, when it happened, how late it appeared, and what context is attached.

Trade range

$1K – $15K

Filed

2026-03-24

Trade date

2026-02-13

Disclosure lag

39 days after trade

Why this receipt matters

A quick read before you share it.

These are factual context points from the receipt and linked public-record data. They explain why the disclosure may be worth opening, not whether anyone acted improperly.

Official public filing linked

1The receipt links to an official public filing, so readers can verify the underlying disclosure before sharing.

2The filing appeared 39 days after trade, which helps separate trade timing from filing timing.

3The disclosed range is $1K – $15K, which is the public reporting band rather than an exact profit or loss figure.

410 nearby same-ticker disclosures appeared in the surrounding 30-day window.

5Committee context is available for Angus King, but PoliWealth treats it as context - not proof of intent or wrongdoing.

6Related public-record context includes 32 lobbying filings.

Methodology Data sources Report a correctionDownload CSV row Download source packet

Source

Official filing ↗

Source: official House/Senate financial disclosure record · filing ID 09b9c1ed-1d73-4f17-b6f8-7b2d92021c5b · filed 2026-03-24 · disclosed 39d after transaction

Market context

Eli Lilly and Company

Sector: Healthcare

Vs SPY: -15.7%

Factual flags

32 lobbying filings linked to this ticker.
10 nearby same-ticker disclosures in the surrounding 30-day window.
19 trades filed on 2026-03-24 (batch dump)

Member trail

Angus King

U.S. Senate · ME

Senate Committee on Armed ServicesSenate Committee on Energy and Natural ResourcesSenate Committee on Veterans' AffairsSenate Select Committee on Intelligence

Ticker trail

$LLY

Eli Lilly and Company

Follow this ticker

Alert me when this ticker gets a new congressional receipt. This page reports public disclosures and factual context only. It does not determine intent, is not an accusation, and is not investment advice.